Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi (seladelpar) for adults with primary biliary ...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, ...

GV- and Arch-backed Pelage Pharma is developing a first-of-its-kind topical stem-cell therapy that could redefine the $10B ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...